Research Platform

Alloksys established an integral research network comprising of several academic and biotech collaborations, both nationally and international. Recombinant RESCAP for chronic inflammatory diseases is developed within a partnering ETB program on the novel CAP9 human amnion host cell production platform from CEVEC Pharma, enabling favorable dosing regimes and COG.

Clinical Status

After finalising a phase II clinical trial (see news update April 2008) in prevention of ischemia-reperfusion damage during cardiovascular surgery , Alloksys has started subsequent studies in invasive surgery. A phase IIIa study has been executed in patients undergoing heart valvular surgery in a multi centre international trial. To date, interim evaluation of this phase IIIa trial is ongoing.

Investor Relations

We actively invite parties that wish to be committed to the same objectives and will support us in our endeavour of developing therapeutic proteins that will significantly improve the quality of life of patients that suffer from acute and chronic disabilitating inflammatory diseases. For this purpose we seek investors, contract organisations, biotech companies or pharmaceutical companies that wish to participate in, or co-develop our specific programs, each for which a separately financed business line will be set-up.

Alloksys Life Sciences will further develop the bRESCAP platform technology for application in acute inflammatory conditions , thereby preventing and treating the possible complications of SIRS (systemic inflammatory respons syndrom) , which may progress into a life-threathening  clinical condition having long-term risk for clinical outcome as well as for well being of the affected patients.

AMRIF BV will focus to treatment in chronic unmet medical need diseases. hRESCAP technology, will enter phase 1 trials. Due to the central functional role of RESCVAP as gatekeeper to inflammation, a plethora of chronic diseases and conditions can be targeted. Pending significant investments development in neurodegenerative  diseases  like MS , ALS and Alzheimer Diseases  which all are significant negatively affected by neuroinflammation.   Next Arthritides  diseases and respiratory diseases like asthma/COPD may be targeted.